US Patent 10240152 Compositions and methods for inhibiting expression of transthyretin
Patent 10240152 was granted and assigned to Alnylam Pharmaceuticals on March, 2019 by the United States Patent and Trademark Office.
All edits
Edits on 31 Jul, 2024
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
0
Edits on 17 Apr, 2024
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 9 Dec, 2023
Golden AI
Edits made to:
Article (+181 characters)
Article
Patent abstract
The invention relates to a double-stranded ribonucleic acid (dsRNA) targeting a transthyretin (TTR) gene, and methods of using the dsRNA to inhibit expression of TTR.
Edits on 29 Apr, 2023
Golden AI
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
102401520
Date of Patent
March 26, 2019
0Patent Application Number
153805710
Date Filed
December 15, 2016
0Patent Primary Examiner
Edits on 25 Sep, 2022
Golden AI
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
102401520
Date of Patent
March 26, 2019
0Patent Application Number
153805710
Date Filed
December 15, 2016
0Patent Primary Examiner
Edits on 25 Jan, 2022
Golden AI
Edits made to:
Infobox (+9 properties)
US Patent 10240152 Compositions and methods for inhibiting expression of transthyretin
Infobox
Is a
Patent applicant
Current assignee
Patent jurisdiction
Patent number
10240152
Date of patent
March 26, 2019
Patent application number
15380571
Date Filed
December 15, 2016
Patent primary examiner
Find more entities like US Patent 10240152 Compositions and methods for inhibiting expression of transthyretin
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
